Tango Therapeutics Ownership | Who Owns Tango Therapeutics?

Overview Forecast RevenueFinancials Chart

Tango Therapeutics Ownership Summary

Tango Therapeutics is owned by 115.11% institutional investors, 12.26% insiders. Trv gp iv is the largest institutional shareholder, holding 15.25% of TNGX shares. Fidelity Growth Compy Commingled Pl S is the top mutual fund, with 2.25% of its assets in Tango Therapeutics shares.

TNGX Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Tango Therapeutics	115.11%	12.26%	-27.37%
Sector	Healthcare Stocks	488.17%	11.08%	-399.26%
Industry	Biotech Stocks	306.59%	11.10%	-217.69%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Trv gp iv	16.86M	15.25%	$86.32M
Ecor1 capital	10.63M	9.80%	$32.85M
Tcg crossover management	10.74M	9.71%	$54.97M
Farallon capital management	9.16M	8.28%	$46.88M
Boxer capital	8.20M	7.58%	$70.34M
Adage capital partners gp	5.91M	5.34%	$30.24M
Nextech invest	5.53M	5.10%	$17.10M
Blackrock funding, inc. /de	5.46M	4.94%	$27.97M
Gilead sciences	4.85M	4.47%	$15.00M
Blackrock	3.99M	3.69%	$34.22M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Trv gp iv	16.86M	52.85%	$86.32M
Mass general brigham	354.19K	14.79%	$3.04M
Tcg crossover management	10.74M	6.28%	$54.97M
Boxer capital	8.20M	3.70%	$70.34M
Nextech invest	5.53M	2.77%	$17.10M
Allostery investments lp	40.00K	2.61%	$204.80K
Bain capital life sciences investors	2.71M	1.74%	$13.89M
Trv gp vi	194.17K	1.55%	$994.17K
Blue owl capital lp	814.42K	1.35%	$4.17M
Ecor1 capital	10.63M	1.24%	$32.85M

Top Buyers

Holder	Shares	% Assets	Change
Adage capital partners gp	5.91M	0.05%	5.91M
Gilead sciences	4.85M	0.97%	4.85M
Farallon capital management	9.16M	0.20%	4.55M
Ra capital management	2.00M	0.17%	2.00M
Blackrock funding, inc. /de	5.46M	0.00%	1.43M

Top Sellers

Holder	Shares	% Assets	Change
Fmr	8.84K	-	-9.37M
Southpoint capital advisors lp	-	-	-5.00M
Ecor1 capital	10.63M	1.24%	-2.70M
Deerfield management company, l.p. (series c)	-	-	-1.54M
Blue owl capital lp	814.42K	1.35%	-1.31M

New Positions

Holder	Shares	% Assets	Change	Value
Adage capital partners gp	5.91M	0.05%	5.91M	$30.24M
Gilead sciences	4.85M	0.97%	4.85M	$15.00M
Ra capital management	2.00M	0.17%	2.00M	$10.24M
Soleus capital management	730.00K	0.25%	730.00K	$3.74M
Candriam s.c.a.	708.81K	0.02%	708.81K	$3.63M

Sold Out

Holder	Change
Nelson, van denburg & campbell wealth management group	-12.00
True wealth design	-16.00
Versant capital management	-28.00
Rothschild investment	-40.00
Nisa investment advisors	-98.00

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Jun 30, 2025	118	-	127,240,303	47.81%	115	1.89%	67	15.52%	28	-28.21%
Mar 31, 2025	121	-11.68%	107,289,095	0.80%	97	1.01%	59	-28.92%	38	40.74%
Dec 31, 2024	71	-41.80%	37,625,298	-62.92%	34	0.40%	41	-25.45%	13	-63.89%
Sep 30, 2024	122	4.27%	101,468,815	2.91%	93	1.13%	56	-	35	9.38%
Jun 30, 2024	117	-7.14%	98,597,035	0.20%	91	1.10%	56	-3.45%	32	-15.79%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
Fidelity Growth Compy Commingled Pl S	2.42M	2.25%	712.74K
Vanguard Total Stock Mkt Idx Inv	2.16M	1.94%	-47.84K
iShares Russell 2000 ETF	1.83M	1.64%	-34.76K
Fidelity Growth Compy Commingled Pl O	1.69M	1.58%	-
T. Rowe Price Small-Cap Value	1.66M	1.53%	-1.94K
Fidelity Growth Company Fund	1.53M	1.43%	543.72K
Fidelity Small Cap Growth	1.25M	1.17%	-
T. Rowe Price Small-Cap Stock	1.19M	1.11%	199.50K
T. Rowe Price US Small-Cap Core Equity	1.19M	1.11%	277.63K
SPDR® S&P Biotech ETF	1.12M	1.05%	16.00K

Recent Insider Transactions

Date	Name	Role	Activity	Value
Sep 08, 2025	Third Rock Ventures IV, L.P.	-	Sell	$608.63K
Sep 05, 2025	Third Rock Ventures IV, L.P.	-	Sell	$4.50M
Aug 22, 2025	Third Rock Ventures IV, L.P.	-	Sell	$2.12M
Aug 19, 2025	Third Rock Ventures IV, L.P.	-	Sell	$7.71M
Feb 04, 2025	Barry Douglas	General Counsel	Sell	$8.29K

Insider Transactions Trends

Date	Buy	Sell
2025 Q3	-	4
2025 Q2	-	-
2025 Q1	-	8
2024 Q4	2	7
2024 Q3	-	18

TNGX Ownership FAQ

Who Owns Tango Therapeutics?

Tango Therapeutics shareholders are primarily institutional investors at 115.11%, followed by 12.26% insiders and -27.37% retail investors. The average institutional ownership in Tango Therapeutics's industry, Biotech Stocks , is 306.59%, which Tango Therapeutics falls below.

Who owns the most shares of Tango Therapeutics?

Tango Therapeutics’s largest shareholders are Trv gp iv (16.86M shares, 15.25%), Ecor1 capital (10.63M shares, 9.80%), and Tcg crossover management (10.74M shares, 9.71%). Together, they hold 34.76% of Tango Therapeutics’s total shares outstanding.

Does Blackrock own Tango Therapeutics?

Yes, BlackRock owns 3.69% of Tango Therapeutics, totaling 3.99M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 34.22M$. In the last quarter, BlackRock increased its holdings by 126.49K shares, a 3.28% change.

Who is Tango Therapeutics’s biggest shareholder by percentage of total assets invested?

Trv gp iv is Tango Therapeutics’s biggest shareholder by percentage of total assets invested, with 52.85% of its assets in 16.86M Tango Therapeutics shares, valued at 86.32M$.

Who is the top mutual fund holder of Tango Therapeutics shares?

Fidelity Growth Compy Commingled Pl S is the top mutual fund holder of Tango Therapeutics shares, with 2.25% of its total shares outstanding invested in 2.42M Tango Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools